Chemistry:PF-07321332

PF-07321332
Legal status
Legal status	US: Investigational drug ;
Identifiers
	IUPAC name (1R,2S,5S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;
CAS Number	2628280-40-8;
PubChem CID	155903259;
Chemical and physical data
Formula	C23H32F3N5O4
Molar mass	499.535 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(F)(F)F)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C;
	InChI InChI=1S/C23H32F3N5O4/c1-21(2,3)16(30-20(35)23(24,25)26)19(34)31-10-13-14(22(13,4)5)15(31)18(33)29-12(9-27)8-11-6-7-28-17(11)32/h11-16H,6-8,10H2,1-5H3,(H,28,32)(H,29,33)(H,30,35)/t11-,12-,13-,14-,15-,16+/m0/s1; Key:LIENCHBZNNMNKG-OJFNHCPVSA-N;

PF-07321332 is an antiviral drug developed by Pfizer which acts as an orally active 3CL protease inhibitor. It is in Phase 3 trials for the treatment of COVID-19 in combination with ritonavir.^[1]^[2]^[3]^[4]^[5]^[6]

References

0.00

(0 votes)

Legal status

Legal status	US: Investigational drug
Identifiers
IUPAC name (1R,2S,5S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
CAS Number	2628280-40-8
PubChem CID	155903259
Chemical and physical data
Formula	C₂₃H₃₂F₃N₅O₄
Molar mass	499.535 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(F)(F)F)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C
InChI InChI=1S/C23H32F3N5O4/c1-21(2,3)16(30-20(35)23(24,25)26)19(34)31-10-13-14(22(13,4)5)15(31)18(33)29-12(9-27)8-11-6-7-28-17(11)32/h11-16H,6-8,10H2,1-5H3,(H,28,32)(H,29,33)(H,30,35)/t11-,12-,13-,14-,15-,16+/m0/s1 Key:LIENCHBZNNMNKG-OJFNHCPVSA-N